CALIXAR offers a unique and patented technological platform allowing to isolate in solution – with the highest purity levels – full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays.
CALIXAR’s approach allows to preserve the original structure and function of membrane proteins (GPCRs, Ion Channels, Transporters, Receptors, Anchors and Viral Proteins) providing solutions for pharmaceutical industries, biotechnology companies and academic teams to develop conformational antibodies, formulate new vaccines, carry out Structure Based Drug Discovery and/or HTS assays. Moreover, the expertise is also specifically adapted to downstream processing (DSP) as well as upstream processing (USP – expression part).
To overcome this crucial issue, our company develops new tools and protocols for the deorphanization, identification, expression, extraction, purification, stabilization, structural functional characterization, crystallization of membrane proteins as well as detergent quantification. The starting biological material (virus, bacteria, primary cells, organs,…) can be endogenous or recombinant systems. CALIXAR uses original, innovative and customized chemistry that aims to adapt to the biochemical characteristics of the target during the solubilization/ purification/stabilization steps.
New grant for membrane protein stabilization chemistry
CALIXAR, the French biotech company specialized in the native isolation of membrane therapeutic targets/antigens and the French University of Avignon – Bio-organic Chemistry and Amphiphilic Systems Team (CBSA) – announce new grant approval for the CHEM2STAB common laboratory (CHEMistry for STABilization) from the French National Research Agency (ANR).
14 November 2019
New vaccine formulation against influenza infection
Calixar announces the publication of a new article in Vaccine by Calixar in collaboration with the VirPath laboratory (Lyon) and International infectious diseases Research Center, Quebec (Laval University). This publication describes an improved process to formulate the influenza vaccine since it allows the same protection in animals and neutralizing antibody responses but with 10 to 30-fold less antigen than the commercialized trivalent inactivated vaccines Vaxigrip® or Fluviral®.
24 October 2019
Novel influenza vaccine : Calixar patent granted in Europe
After the United States Patent Office in last June, CALIXAR announces the grant of its patent by the European Patent Office concerning the preparation of vaccine antigens using an innovative splitting approach for the formulation of novel vaccines (EP3194433). This patent issued from the fruitful collaboration with the academic laboratory VirPath is a great step forward in the generation of safer and more efficient vaccine candidates.
15 October 2019